Dupixent

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

News

Can Dupixent plug treatment gap in bullous pemphigoid?

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Dupixent is first FDA-approved drug for rare skin disease

GSK claims first approval for Nucala in COPD

GSK sets up Nucala and Dupixent showdown in COPD

Sanofi's Dupixent gets FDA nod for chronic hives indication

Can Dupixent plug treatment gap in bullous pemphigoid?

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Dupixent

Editor's Picks